
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell Inc. is anticipating revenues of $87 million to $89 million for 2025, reflecting a year-over-year growth of 33% to 36%, and is demonstrating strong commercial traction through investments in its salesforce and product pipeline. The company is positioned for long-term success with plans to expand market presence across various healthcare settings, including VA hospitals and pediatric populations, while also targeting new medical indications. With gross margins in the mid-80% range, CeriBell's focus on operational leverage presents a compelling pathway to enhanced profitability as it scales its innovative technology.
Bears say
CeriBell Inc. is currently not free cash flow positive and reported a substantial net loss of $40 million in the most recent year, indicating ongoing financial struggles. The company is also facing near-term margin pressures, notably due to potential increases in tariffs and legal expenses, which could lead to reduced gross margins and increased reliance on alternative sourcing, further complicating its supply chain dynamics. Additionally, the broader market risks, including potential changes in customer demand, competitive pressures, and financial uncertainties, contribute to a challenging outlook for the company's future profitability and investment attractiveness.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares